Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Stomach Neoplasms 13Lung Neoplasms 9Adenocarcinoma 5Neoplasms 4Neoplasm Metastasis 4Esophageal Neoplasms 4Adenocarcinoma Of Esophagus 3Squamous Cell Carcinoma of Head and Neck 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Thymoma 1Solid Tumors 1Solid Cancer 1Sarcoma 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neoplasms by Site 1Metastatic Small Intestinal Adenocarcinoma 1Metastatic Gastric Adenocarcinoma 1Melanoma 1Lymphoma, Non-Hodgkin 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Digestive System Neoplasms 1Desmoplastic Small Round Cell Tumor 1Clinical Stage IVB Gastric Cancer AJCC v8 1

Interventions

Gemcitabine 32Cisplatin 31durvalumab 15pembrolizumab 14Fluorouracil 13Oxaliplatin 12Leucovorin 12Capecitabine 10Bevacizumab 8lenvatinib 7Nivolumab 7zanidatamab 4Trastuzumab 4S 1 (combination) 4Paclitaxel 4Liquid Biopsy 4Irinotecan 4Carboplatin 4Albumin-Bound Paclitaxel 4tremelimumab 3tislelizumab 3irinotecan sucrosofate 3Injections 3Folfox protocol 3130-nm albumin-bound paclitaxel 3toripalimab 2pertuzumab 2niraparib 2ivosidenib 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Ramucirumab × 1 year × Clear all
NCT02711553 2025-08-03

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Eli Lilly and Company

Phase 2 Active not recruiting
309 enrolled 22 charts
Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡